During the meeting, the role of the Vall d'Hebron Paediatric Research Hub in promoting research on children and adolescents was highlighted.

The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

This appointment is an international recognition of VHIR's immunodeficiency research.

So far, 240 volunteers have been recruited within all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

The results show that, in some patients with mutations in the X chromosome, the healthy gene is inactivated and the mutated gene manifests itself, which favors the onset of the disease.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

As part of the initiative, WikiTropica, a tool that provides health professionals with up-to-date information on infectious and tropical diseases, has been launched.

The project aims to test the HIPRA vaccine against COVID-19 in children (including adolescents) and immunocompromised people.

The meeting, in which Dr. Pere Soler participated, showed the results of the first year with the description of new genetic defects associated with severe forms of COVID-19 and novelties in the detection of autoantibodies against interferons.

The platform offers health workers the latest information on infectious and tropical diseases and also serves as a training tool.

This clinical trial is part of the RBDCOV project to test the vaccine on adolescents aged from 12 to 18.

Representants de la Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria de Vall d’Hebron i el grup de recerca d'Infecció i Immunitat al pacient pediàtric del VHIR van participar en taules rodones al congrés i van rebre premis.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.

Els actes amb motiu del Dia de les Malalties Minoritàries fan possible que pacients amb malalties diferents es trobin i s’ajudin

The funds will be used to maintain the contract of the psychologist who monitors the emotional well-being of the children with primary immunodeficiencies.

The PhD student of the research group Infection in the immunocompromised pediatric patient has received one of the Junior Talent Awards given by the organization.

The donation allows to advance in the research of the mechanisms of primary immunodeficiencies and to evaluate the pathogenicity of mutations in patients.

The article on the mortality rate of young people with HIV due to perinatal transmission after transitioning to adult health care in Spain received the PIDJ award.

The work was one of the first to identify skin lesions associated with SARS-CoV-2 infection in children at the beginning of the pandemic.

The publication summarises the main results showing that at least 20% of cases of severe pneumonia after SARS-CoV-2 infection are explained by genetic and immunological anomalies.

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.